Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFIRINOX + gemcitabine (Università Campus Bio-Medico di Roma)
- Development stage
- Unknown
- Lead developer
- Università Campus Bio-Medico di Roma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FOLFIRINOX + gemcitabine is a combination chemotherapy regimen evaluated by Campus Bio-Medico University for the treatment of pancreatic ductal adenocarcinoma. The regimen consists of an induction phase using the FOLFIRINOX protocol—a combination of oxaliplatin (a platinum-based DNA alkylating agent), irinotecan (a topoisomerase I inhibitor), leucovorin (a folate analog that enhances the activity of fluorouracil), and fluorouracil (a pyrimidine analog and thymidylate synthase inhibitor). This is followed by a consolidation phase involving weekly gemcitabine (a nucleoside analog that inhibits DNA synthesis) administered concurrently with radiation therapy. This sequential approach is designed to provide systemic control of micrometastatic disease while intensifying local treatment for locally advanced or borderline resectable pancreatic tumors.
- Other names
- Induction FOLFIRINOX followed by gemcitabine-based chemoradiationFOLFIRINOX followed by gemcitabineoxaliplatin + irinotecan + leucovorin + fluorouracil + gemcitabine
02
Targets
RNR (Ribonucleotide reductase)TS (Thymidylate synthase)DNA polymerase familyTOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on FOLFIRINOX + gemcitabine (Università Campus Bio-Medico di Roma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFIRINOX + gemcitabine (Università Campus Bio-Medico di Roma).